ADDISON, TX / ACCESSWIRE / December 8, 2016 / Wound Management Technologies, Inc. (OTC QB: WNDM) announced today that J. Michael (Mike) Carmena has been engaged as the Chief Financial Officer effective immediately. Mr. Carmena adds 35 years of broad-based Financial and Operations experience to the Company's management team, with 15 years of experience in the Life Sciences sector. In Life Sciences, Mike served as Senior Director, Business & Sales Operations of Smith and Nephew plc's Biotherapeutics' Division, formerly known as Healthpoint Biotherapeutics; as Healthpoint's Senior Director, Finance & Administration; and as Controller.

After graduating, magna cum laude, with a BBA in Accounting from Texas Christian University in 1978, Mr. Carmena began his professional career at Arthur Andersen & Co. and became a Texas CPA in 1981. In addition to his Life Sciences experience, he has held senior financial positions in oil and gas exploration and production, ranching, and financial asset management. He has also served as a board advisor for a pharmaceutical manufacturer and railroad equipment manufacturer.

"The Wound Management Technologies Board of Directors and I are excited to have Mike join our management team," said Deborah Hutchinson, President. "Mike's financial experience coupled with his sales and marketing orientation makes him an ideal team member as we continue to expand and grow our business. We feel fortunate to add his financial and strategic planning skills to our team to support our growing sales network for CellerateRX® Activated Collagen® products coupled with the upcoming launch of HemaQuell™ Resorbable Bone Wax."

About Wound Management Technologies

Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its Wound Care Innovations subsidiary's unique, patented collagen product line, CellerateRX(R) which is FDA-cleared for all wound types except 3rd degree burns. The Resorbable Orthopedic Products subsidiary owns a multi-faceted bone wax and bone void filler patent and markets products in the $1.5B biomaterials market and is anticipating new revenues from HemaQuell Resorbable Bone Wax. For more information visit our newly updated website,

Information about Forward-Looking Statements

The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the Company's actual operating results, performance, or business plans or prospects to differ materially from those expressed in, or implied by, these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contacts:
Investor Relations

SOURCE: Wound Management Technologies, Inc.